This guide is for US brands entering the EU and for brands selling in both markets.
What does MoCRA require for safety substantiation?
MoCRA requires the responsible person to "ensure, and maintain records supporting, that there is adequate substantiation of safety" of each cosmetic product (FD&C Act section 608(a)). The Modernization of Cosmetics Regulation Act of 2022 was enacted on 29 December 2022. Since 29 December 2023, a product is deemed adulterated if it, or any of its ingredients, lacks adequate substantiation of safety (section 601(g)).
The definition is about evidence, not form: "tests or studies, research, analyses, or other evidence or information" that qualified experts would consider "sufficient to support a reasonable certainty that a cosmetic product is safe." The FDA says that "neither the law nor FDA regulations require specific tests," and in a July 2026 Federal Register notice it wrote that responsible persons "have discretion in determining which records satisfy this requirement." A US safety file can therefore be a formal report or a folder of supplier data and test results.
What does the EU require in a CPSR?
The EU requires a cosmetic product safety report "set up in accordance with Annex I" before the product is placed on the market (Article 10(1) of Regulation (EC) No 1223/2009). Part A holds the data in 10 sections; Part B holds the conclusion, label warnings, reasoning and the assessor's signature.
Two requirements have no US counterpart. Part A section 8 says a margin of safety (MoS) based on a NOAEL "shall be calculated", or its absence "duly justified". And Part B must name and be signed by an assessor with a university qualification in pharmacy, toxicology, medicine or a similar discipline (Article 10(2)). The CPSR is kept in the Product Information File (PIF) with the product description, a GMP statement, claim evidence and animal testing data (Article 11). Our guide to Part A and Part B covers each section.
Who is the "responsible person" in each system?
Both laws use the term but define it differently. Under MoCRA it is "the manufacturer, packer, or distributor of a cosmetic product whose name appears on the label" (FD&C Act section 604(4)). The definition depends on the name on the label, not on where the company is based.
In the EU, a product can be placed on the market only if a person is "designated within the Community" as responsible person (Article 4(1)). For imports, the importer is the responsible person or appoints one in the EU by written mandate (Article 4(5)). A company with no EU establishment cannot be its own EU responsible person, and an EU responsible person does not take on US duties. See our guide to CPSR, PIF, CPNP and the Responsible Person.
How do MoCRA and the EU rules compare side by side?
The main differences are the document format, the signature and the timing of notification.
| United States (MoCRA) | European Union (Reg. 1223/2009) | |
|---|---|---|
| Who is responsible | Manufacturer, packer or distributor named on the label (FD&C 604) | Person designated in the EU (Art. 4) |
| Safety document | Records supporting adequate substantiation of safety (FD&C 608) | CPSR under Annex I, kept in the PIF (Art. 10, 11) |
| Format | Not prescribed | Fixed: Part A (10 sections), Part B (4 sections) |
| Signed by a qualified assessor? | Not required | Required (Art. 10(2), Annex I Part B) |
| Notification or listing | Facility registration (renewed every 2 years) and product listing within 120 days of marketing (FD&C 607) | CPNP notification before placing on the market (Art. 13) |
| Record keeping | Adverse event records 6 years (3 for some small businesses); no period set in section 608 | PIF kept 10 years after the last batch (Art. 11) |
| Fragrance allergens on the label | Required once the FDA issues its rule (FD&C 609(b)); no proposed rule found as of 14 November 2026 | Annex III allergens above 0.001 % leave-on, 0.01 % rinse-off; expanded list for products placed on the market from 1 August 2026 |
| Adverse events | Serious adverse events to the FDA within 15 business days, with the label (FD&C 605) | Serious undesirable effects, without delay, to the authority of the member state where they occurred (Art. 23) |
| Contact on the label | US address, US phone or electronic contact for adverse event reports (FD&C 609(a)) | Name and address of the EU responsible person; country of origin for imports (Art. 19) |
Which evidence can be reused between a US safety file and an EU CPSR?
Most of the underlying science can be reused, because both systems accept existing data. The FDA says manufacturers "can use safety data that is already available on individual ingredients and on products with similar formulations." The Commission's Annex I guidelines (Decision 2013/674/EU) say Part A data "can be drawn from any reliable source", including supplier data and studies on similar formulations.
These items usually transfer to the EU dossier:
- Raw material data: specifications, safety data sheets, certificates of analysis, supplier toxicology.
- Ingredient toxicology: published studies and Cosmetic Ingredient Review (CIR) reports. The FDA says it takes CIR reviews "into consideration"; an EU assessor treats them as one source among others.
- Stability and packaging compatibility tests on the finished product.
- Microbiology: microbial limits and challenge test results, which Annex I Part A section 3 requires.
- Human studies and US complaint history (Part A sections 9 and 10).
The EU assessor still decides whether each piece of data is relevant and sufficient for the EU product.
What does an EU CPSR need that a US file often lacks?
Four things are often missing:
- The exact quantitative formula. The Commission guidelines say ranges "should not be used" unless justified. For a fragrance, the CPSR needs the composition's name, code and supplier.
- Exposure and MoS calculations for each relevant ingredient (Part A sections 6 to 8).
- A check against EU Annexes II to VI, the EU lists of prohibited and restricted substances, colorants, preservatives and UV filters. A US formula has not necessarily been checked against them.
- A signed Part B with the label warnings the EU requires.
Animal studies in your US file must also be recorded in the PIF (Article 11(2)(e)), and the assessor checks them against the Article 18 bans.
What does MoCRA require that an EU CPSR does not cover?
A CPSR covers none of the US procedural duties. Facility registration and product listing (in Cosmetics Direct or by other FDA routes), serious adverse event reports and US labelling stay with the US responsible person.
The small business exemption is narrow. Companies with average gross annual US cosmetics sales under $1,000,000 over the previous three years (adjusted for inflation) are exempt only from GMP and registration/listing (section 612), not from safety substantiation or adverse event reporting. The exemption does not apply to makers of certain products, such as products that contact the mucous membrane of the eye or injected products.
Where do fragrance allergen and GMP rules stand in the US?
Both are still pending. Section 609(b) requires fragrance allergens on the label; the FDA must set the list by regulation and consider "the substance and format of requirements in the European Union". Section 606 requires a GMP regulation. As of 14 November 2026, the FDA's MoCRA page still lists both among the rules MoCRA requires the FDA to establish, and we found no proposed rule for either in the Federal Register. The GMP guidance it links is a 2013 draft it intends to withdraw or revise.
In the EU, both apply now. Article 8 requires GMP, and the PIF must include a GMP statement. Annex III allergens above 0.001 % (leave-on) or 0.01 % (rinse-off) must be named in the ingredient list, using the list expanded by Regulation (EU) 2023/1545 for products placed on the market from 1 August 2026. A US label that says only "fragrance" will need changes if any listed allergen is above the threshold.
I already have a MoCRA file or a CPSR. What should I do?
If you have a MoCRA safety file and want to enter the EU:
- Appoint an EU responsible person (your importer or an RP service).
- Collect the exact formula, raw material documents, allergen declaration, stability and microbiology reports and the label (see our document checklist).
- Have an EU safety assessor write the CPSR, reusing your data and filling the gaps (usually exposure, MoS and the annex check).
- Adapt the label to Article 19, assemble the PIF and notify in CPNP.
If you have an EU CPSR and want to enter the US: your CPSR and PIF data are a good starting point for US safety records. Whether they amount to adequate substantiation for the US product is for your US responsible person to decide. Registration, listing, adverse event reporting and US labelling are separate tasks.
Can Notium help with the US side?
No. We prepare EU CPSRs and help assemble the PIF for the EU market only. US registration and listing, adverse event reporting, US labelling and the US safety file are for your US responsible person or US regulatory counsel.
For the EU, send your US safety file, formula, test reports and label. We will tell you what can be reused and what is missing.
FAQ
Does the FDA accept an EU CPSR as MoCRA safety substantiation?
We found no FDA statement that an EU CPSR automatically satisfies section 608. The law names no format, and the FDA leaves the choice of records to the responsible person. A CPSR can be among those records, but whether the evidence is adequate for the US product is the US responsible person's decision.
Can I use my MoCRA safety file to sell in the EU?
Not on its own. Article 10 requires a CPSR under Annex I, signed by an assessor qualified under Article 10(2). Your US data can go into that CPSR where it is relevant.
Do I need an EU address on the label if it already has a US contact?
Yes. Article 19(1)(a) requires the name and address of the EU responsible person and, for imports, the country of origin. The US contact required by MoCRA does not replace it.
Is an FDA registration or listing number proof of safety in the EU?
No. The FDA says a registration or listing number "does not indicate FDA approval", and it issues no certificates. There is no EU cosmetics certificate either: EU authorities look at the CPSR, the PIF and the CPNP notification.
Sources
- Modernization of Cosmetics Regulation Act of 2022: enrolled text of H.R. 2617, Division FF, Title III, Subtitle E (pages 1389–1402)
- Federal Food, Drug, and Cosmetic Act, Chapter VI, 21 U.S.C. 361–364j: United States Code, 2024 edition, US Government Publishing Office (sections 601, 604–612)
- FDA: Modernization of Cosmetics Regulation Act of 2022 (MoCRA): FDA overview and status of required rules
- FDA: Registration & Listing of Cosmetic Product Facilities and Products: Cosmetics Direct; FDA issues no certificates
- FDA: Product Testing of Cosmetics: use of existing safety data, CIR, microbiology
- FDA notice, 91 FR 44850 (17 July 2026): information collection on cosmetic product requirements, including safety substantiation records
- FDA: Draft Guidance for Industry, Cosmetic Good Manufacturing Practices (2013)
- Regulation (EC) No 1223/2009 on cosmetic products: Articles 4, 8, 10, 11, 13, 18, 19, 23 and Annexes I–VI
- Commission Implementing Decision 2013/674/EU: guidelines on Annex I
- Commission Regulation (EU) 2023/1545: labelling of fragrance allergens